Catapult Capital Management’s Charles River Laboratories CRL Stock Holding History

Catapult Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-10,000	Closed	-$703K	–	165
2015 Q2	$703K	Sell	10,000 -35,000	-78%	-$2.59M	0.1%	190
2015 Q1	$3.57M	Buy	45,000 +25,000	+125%	+$1.84M	0.44%	80
2014 Q4	$1.27M	Buy	+20,000	New	+$1.25M	0.32%	98
2014 Q2	–	Sell	-50,000	Closed	-$3.02M	–	203
2014 Q1	$3.02M	Buy	+50,000	New	+$2.91M	0.6%	54

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Catapult Capital Management's CRL Position: Q3 2015 in Review

Catapult Capital Management sold out of Charles River Laboratories (CRL) in Q3 2015, closing a stake of 10,000 shares — an estimated $703K sold.

Catapult Capital Management first reported a position in CRL in Q1 2014 and held it in 4 quarters. The position peaked at $3.57M in Q1 2015. 258 funds tracked by Wall St. Rank hold CRL as of Q3 2015.

Catapult Capital Management reported no remaining Charles River Laboratories position as of Q3 2015 after selling out during the quarter.
Catapult Capital Management sold 10,000 Charles River Laboratories shares in Q3 2015, an estimated $703K.
Catapult Capital Management first reported a position in Charles River Laboratories in Q1 2014 and held it in 4 quarters.
Catapult Capital Management's Charles River Laboratories position peaked at $3.57M in Q1 2015.
258 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.